checkAd
    Startseite > Aktien > Immutep > Nachrichten
    Immutep Aktie
    0,2600
     
    EUR
    -2,62 %
    -0,0070 EUR
    Letzter Kurs 30.04.24 Lang & Schwarz
    0,2420
     
    EUR
    2.012 STK
    Geldkurs 30.04.24
    0,2780
     
    EUR
    2.012 STK
    Briefkurs 30.04.24
    ISIN: AU000000IMM6 · WKN: A2H81H · Australien

    Neueste Nachrichten

    Immutep Quarterly Activities Report Q3 FY24
    29.04.24 · globenewswire · Immutep
    Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
    24.04.24 · globenewswire · Immutep
    Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
    18.04.24 · globenewswire · Immutep
    Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
    17.04.24 · globenewswire · Immutep
    Immutep Announces First Clinical Data from 90mg Dosing of Efti
    05.03.24 · globenewswire · Immutep
    Immutep Quarterly Activities Report Q2 FY24
    30.01.24 · globenewswire · Immutep
    First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer
    04.01.24 · globenewswire · Immutep
    Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
    21.12.23 · globenewswire · Immutep
    Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial
    22.11.23 · globenewswire · Immutep
    Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
    09.11.23 · globenewswire · Immutep
    Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer
    06.11.23 · globenewswire · Immutep
    Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer
    03.11.23 · globenewswire · Immutep